MCID: SRS001
MIFTS: 55

Serous Cystadenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Serous Cystadenocarcinoma

MalaCards integrated aliases for Serous Cystadenocarcinoma:

Name: Serous Cystadenocarcinoma 12 14
Cystadenocarcinoma, Serous 41 69
Serous Cystadenocarcinoma, Nos 12
Cystadenocarcinoma Serous 51
Serous Adenocarcinoma 12
Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3114
MeSH 41 D018284
NCIt 46 C3778 C40101
SNOMED-CT 64 189685001 90725004
UMLS 69 C0206701

Summaries for Serous Cystadenocarcinoma

Disease Ontology : 12 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards based summary : Serous Cystadenocarcinoma, also known as cystadenocarcinoma, serous, is related to primary peritoneal carcinoma and ovary serous adenocarcinoma. An important gene associated with Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Gene Expression and GPCR Pathway. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 72 Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma... more...

Related Diseases for Serous Cystadenocarcinoma

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)
# Related Disease Score Top Affiliating Genes
1 primary peritoneal carcinoma 33.2 PGR TP53 VEGFA
2 ovary serous adenocarcinoma 32.0 UBE4A USP2 ZNF217
3 ovarian serous cystadenocarcinoma 30.9 AKT1 BCL2 ESR2 PGR UBE4A USP14
4 cystadenocarcinoma 30.3 AKT1 ALPP CDKN1A ESR2 PGR TP53
5 endometriosis 29.3 ESR2 MMP2 PGR VEGFA
6 ovarian cancer 26.5 AKT1 ALPP BCL2 BIRC5 CDKN1A ESR2
7 pancreatic serous cystadenocarcinoma 12.3
8 ovarian serous carcinoma 12.1
9 papillary serous adenocarcinoma 11.8
10 uterine corpus serous adenocarcinoma 11.4
11 endometrium carcinoma in situ 10.6 PGR TP53
12 vestibular gland benign neoplasm 10.5 PGR TP53
13 bartholin's gland adenoma 10.5 PGR TP53
14 female reproductive endometrioid cancer 10.5 PGR TP53
15 breast malignant phyllodes tumor 10.5 PGR TP53
16 olfactory groove meningioma 10.5 PGR TP53
17 progesterone resistance 10.5 ESR2 PGR
18 actinic cheilitis 10.4 CDKN1A TP53
19 progesterone-receptor positive breast cancer 10.4 ESR2 PGR
20 bartholin's gland benign neoplasm 10.4 PGR TP53
21 invasive bladder transitional cell carcinoma 10.4 CDKN1A TP53
22 uterine body mixed cancer 10.4 ESR2 PGR TP53
23 uterine carcinosarcoma 10.4 ESR2 PGR TP53
24 gastrointestinal neuroendocrine tumor 10.4 CDKN1A VEGFA
25 estrogen-receptor positive breast cancer 10.4 AKT1 PGR TP53
26 fallopian tube carcinoma 10.3 PGR TP53 VEGFA
27 malignant germ cell tumor 10.3 ALPP ESR2
28 ductal carcinoma in situ 10.3 AKT1 PGR TP53
29 atypical follicular adenoma 10.3 CDKN1A TP53
30 breast carcinoma in situ 10.3 PGR TP53 VEGFA
31 sporadic breast cancer 10.3 ESR2 PGR TP53
32 connective tissue cancer 10.3 AKT1 TP53 VEGFA
33 breast disease 10.3 ESR2 PGR TP53
34 female reproductive system disease 10.3 ESR2 PGR VEGFA
35 pancreas adenocarcinoma 10.3 AKT1 TP53 VEGFA
36 lip cancer 10.3 CDKN1A TP53
37 pancreatic serous cystadenoma 10.3 PGR VEGFA
38 sensory system cancer 10.3 AKT1 CDKN1A TP53
39 squamous cell carcinoma of the larynx 10.3 BCL2 TP53
40 gender identity disorder 10.2 ESR2 PGR
41 myeloma, multiple 10.2 AKT1 TP53 VEGFA
42 chordoid glioma 10.2 PGR TP53
43 bladder transitional cell papilloma 10.2 BIRC5 CDKN1A TP53
44 brain cancer 10.2 AKT1 TP53 VEGFA
45 pancreatitis 10.2
46 peritonitis 10.2
47 endometrial adenocarcinoma 10.2 ESR2 PGR TP53 VEGFA
48 benign metastasizing leiomyoma 10.2 BCL2 PGR
49 gastric lymphoma 10.2 BCL2 TP53 VEGFA
50 soft tissue sarcoma 10.2 BCL2 TP53 VEGFA

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:



Diseases related to Serous Cystadenocarcinoma

Symptoms & Phenotypes for Serous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 AKT1 BCL2 BIRC5 CDKN1A TP53 USP14
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 AKT1 BCL2 BIRC5 CDKN1A TP53 USP14

MGI Mouse Phenotypes related to Serous Cystadenocarcinoma:

43 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 MMP14 ESR2 AKT1 BIRC5 CDKN1A BCL2
2 behavior/neurological MP:0005386 10.35 MMP14 ESR2 CDKN1A BCL2 AKT1 PGR
3 cardiovascular system MP:0005385 10.35 MMP14 ESR2 AKT1 CDKN1A BCL2 MMP2
4 homeostasis/metabolism MP:0005376 10.35 MMP14 ESR2 AKT1 BIRC5 CDKN1A BCL2
5 endocrine/exocrine gland MP:0005379 10.31 MMP14 ESR2 AKT1 BIRC5 CDKN1A BCL2
6 hematopoietic system MP:0005397 10.29 MMP14 ESR2 CDKN1A BCL2 AKT1 BIRC5
7 growth/size/body region MP:0005378 10.26 ESR2 CDKN1A BCL2 AKT1 TP53 MMP14
8 immune system MP:0005387 10.26 CDKN1A MMP14 ESR2 BCL2 AKT1 BIRC5
9 mortality/aging MP:0010768 10.26 CDKN1A MMP14 ESR2 BCL2 AKT1 BIRC5
10 embryo MP:0005380 10.23 MMP14 CDKN1A BCL2 AKT1 BIRC5 PGR
11 integument MP:0010771 10.21 MMP14 ESR2 AKT1 CDKN1A BCL2 TP53
12 muscle MP:0005369 10.2 MMP14 ESR2 AKT1 CDKN1A BCL2 MMP2
13 digestive/alimentary MP:0005381 10.13 ESR2 CDKN1A MMP14 BCL2 TP53 VEGFA
14 nervous system MP:0003631 10.1 CDKN1A MMP14 ESR2 BCL2 AKT1 TP53
15 adipose tissue MP:0005375 10.09 ESR2 CDKN1A MMP14 BCL2 AKT1 TP53
16 neoplasm MP:0002006 10.09 ESR2 AKT1 CDKN1A BCL2 MMP2 TP53
17 craniofacial MP:0005382 10.07 CDKN1A BCL2 TP53 MMP14 MMP2 VEGFA
18 limbs/digits/tail MP:0005371 9.97 ESR2 CDKN1A MMP14 TP53 PGR VEGFA
19 normal MP:0002873 9.92 MMP14 ESR2 AKT1 BIRC5 TP53 PGR
20 no phenotypic analysis MP:0003012 9.91 CDKN1A MMP14 ESR2 PGR TP53 VEGFA
21 renal/urinary system MP:0005367 9.86 MMP14 ESR2 CDKN1A BCL2 TP53 YAP1
22 reproductive system MP:0005389 9.85 MMP14 ESR2 BCL2 AKT1 CDKN1A PGR
23 respiratory system MP:0005388 9.56 MMP14 ESR2 CDKN1A AKT1 MMP2 TP53
24 skeleton MP:0005390 9.28 CDKN1A MMP14 ESR2 AKT1 PGR MMP2

Drugs & Therapeutics for Serous Cystadenocarcinoma

Drugs for Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 190)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
5
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
7
Epirubicin Approved Phase 3 56420-45-2 41867
8
Topotecan Approved, Investigational Phase 2, Phase 3, Phase 1 119413-54-6, 123948-87-8 60700
9
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
10
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
11
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
12
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
13
Letrozole Approved, Investigational Phase 2, Phase 3, Early Phase 1 112809-51-5 3902
14
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
15
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
16
Metformin Approved Phase 2, Phase 3,Phase 1,Early Phase 1 657-24-9 4091 14219
17
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
18
Olaparib Approved Phase 2, Phase 3,Phase 1,Early Phase 1 763113-22-0 23725625
19
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
20
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
21
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
23
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
24
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
25
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
26
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
27 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
28 Antimitotic Agents Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
30 Hormones Phase 2, Phase 3, Early Phase 1
31 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
32 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
33 Antibodies Phase 3,Phase 2,Phase 1
34 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
35 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
36 Immunoglobulins Phase 3,Phase 2,Phase 1
37 Mitogens Phase 3,Phase 2,Phase 1
38 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
39 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
40 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
41 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
42 Liver Extracts Phase 3,Phase 2,Phase 1
43 Antineoplastic Agents, Hormonal Phase 2, Phase 3
44 Hormone Antagonists Phase 2, Phase 3, Early Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3, Early Phase 1
46 Protein Kinase Inhibitors Phase 2, Phase 3, Phase 1
47 topoisomerase I inhibitors Phase 2, Phase 3, Phase 1
48 Antifungal Agents Phase 2, Phase 3,Phase 1
49 Anti-Infective Agents Phase 2, Phase 3, Phase 1
50 Immunosuppressive Agents Phase 2, Phase 3, Phase 1

Interventional clinical trials:

(show top 50) (show all 156)

# Name Status NCT ID Phase Drugs
1 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
2 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
7 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
8 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
9 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
10 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
11 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
12 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
13 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
14 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
15 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
16 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
17 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
18 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
19 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
20 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
21 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
22 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
23 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
24 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
25 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
26 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
27 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
28 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
29 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
30 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
31 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
32 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
33 Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Unknown status NCT00003560 Phase 2 carboplatin;docetaxel
34 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
35 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
36 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
37 Phase II ABT-888 With Cyclophosphamide Completed NCT01306032 Phase 2 ABT-888;Cyclophosphamide
38 Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Completed NCT00022620 Phase 2 paclitaxel
39 Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer Completed NCT01583322 Phase 2 vargatef;placebo
40 Uterine Papillary Serous Cancer (UPSC) Trial Completed NCT00147680 Phase 2 Paclitaxel, Carboplatin
41 A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus Completed NCT00231842 Phase 2 Ifosfamide
42 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
43 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
44 Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer Completed NCT00052312 Phase 2 cisplatin;doxorubicin hydrochloride;paclitaxel
45 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00275028 Phase 2 cediranib maleate
46 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
47 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
48 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
49 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
50 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide

Search NIH Clinical Center for Serous Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma, serous

Genetic Tests for Serous Cystadenocarcinoma

Anatomical Context for Serous Cystadenocarcinoma

MalaCards organs/tissues related to Serous Cystadenocarcinoma:

38
Ovary, Pancreas, Liver, Bone, Lymph Node, Uterus, Brain

Publications for Serous Cystadenocarcinoma

Articles related to Serous Cystadenocarcinoma:

(show top 50) (show all 105)
# Title Authors Year
1
Expression of Yes-associated proteinA 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )
2017
2
Serous cystadenocarcinoma of the spleen. ( 28491168 )
2017
3
High Grade Serous Cystadenocarcinoma of Testis-Case Report of a Rare Ovarian Epithelial Type Tumour. ( 28764180 )
2017
4
Serous Cystadenocarcinoma of the Pancreas: Clinical Features and Management of a Rare Tumor. ( 26998825 )
2016
5
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
6
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016
7
Serous Cystadenocarcinoma Arising in Presumed Vitelline Duct Remnant: A Case Report and Implications in the Management of Cancer of Unknown Primary. ( 27999702 )
2016
8
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )
2016
9
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )
2016
10
Synchronous resection of pancreatic serous cystadenocarcinoma and liver metastasis: First reported case and review of literature. ( 26463518 )
2015
11
Solid variant type of serous cystadenocarcinoma of the pancreas: AA case report and review of the literature. ( 25716800 )
2015
12
Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after aggressive surgical resection. ( 26177796 )
2015
13
"Sea anemone-like ciliated tumor cells" in a case of serous cystadenocarcinoma of the ovary. ( 26811576 )
2015
14
Primary Peritoneal Papillary Serous Cystadenocarcinoma - A Rare Malignancy. ( 26713835 )
2015
15
Neoplasms in the trocar site and peritoneal papillary serous cystadenocarcinoma. ( 25017255 )
2014
16
Serous cystadenocarcinoma of the mesentery in a man: case report and review of literature. ( 24759353 )
2014
17
Paratesticular papillary serous cystadenocarcinoma: A rare entity in Indian population. ( 25308020 )
2014
18
Serous cystadenocarcinoma of pancreas. ( 23763806 )
2013
19
IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma. ( 24595078 )
2013
20
Histological percutaneous diagnosis of stage IV microcystic serous cystadenocarcinoma of the pancreas. ( 23370947 )
2013
21
Ovarian serous cystadenocarcinoma metastasising to the breast. ( 23445161 )
2013
22
Serous cystadenocarcinoma of the pancreas: report of a case and management reflections. ( 22400805 )
2012
23
Peritoneal papillary serous cystadenocarcinoma at a previous laparoscopic trocar site. ( 23040941 )
2012
24
Testicular papillary serous cystadenocarcinoma: a rare case report and review of the literature. ( 22355499 )
2011
25
Imaging of pancreatic serous cystadenocarcinoma. ( 22009426 )
2011
26
Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen. ( 22066125 )
2011
27
Serous cystadenocarcinoma of the pancreas with portal thrombosis. ( 20499029 )
2010
28
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. ( 21266826 )
2010
29
Serous cystadenocarcinoma of the ovary in an 11-year-old girl with extensive dissemination and chylothorax: a case report and a brief review of literature. ( 19564753 )
2009
30
Collision tumor: serous cystadenocarcinoma and dermoid cyst in the same ovary. ( 18818939 )
2009
31
Pancreatic serous cystadenocarcinoma: a case report and review of the literature. ( 19459016 )
2009
32
Papillary serous cystadenocarcinoma of the stomach, peritoneum and ovary. ( 20163045 )
2009
33
Serous cystadenocarcinoma of the pancreas with metachronous hepatic metastasis. ( 19060596 )
2008
34
Macrocystic serous cystadenocarcinoma of the pancreas: the first report of a new pattern of pancreatic carcinoma. ( 18305183 )
2008
35
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. ( 18574502 )
2008
36
[Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. ( 17553343 )
2007
37
Plasma cell leukemia with ovarian serous cystadenocarcinoma. ( 17883177 )
2007
38
Immunohistochemical identification of primary peritoneal serous cystadenocarcinoma mimicking advanced colorectal carcinoma: a case report. ( 18036260 )
2007
39
[Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. ( 16793610 )
2006
40
Paratesticular papillary serous cystadenocarcinoma--a case report. ( 16625973 )
2006
41
[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. ( 17160949 )
2006
42
Serous cystadenocarcinoma of the pancreas: management of a rare entity. ( 16025006 )
2005
43
Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. ( 16012716 )
2005
44
Primary papillary serous cystadenocarcinoma of broad ligament. ( 15845057 )
2005
45
Serous cystadenocarcinoma of the pancreas. ( 15982220 )
2005
46
A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior. ( 14551796 )
2004
47
Mean nuclear volume in ovarian papillary serous cystadenocarcinoma. ( 15032078 )
2004
48
Plasma cell leukaemia with papillary serous cystadenocarcinoma of ovary--a case report. ( 15025299 )
2003
49
Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary. ( 12068151 )
2002
50
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. ( 11201519 )
2001

Variations for Serous Cystadenocarcinoma

Expression for Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Serous Cystadenocarcinoma.

Pathways for Serous Cystadenocarcinoma

Pathways related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 AKT1 BIRC5 CDKN1A ESR2 PGR TP53
2
Show member pathways
13.69 AKT1 BCL2 BIRC5 CDKN1A ESR2 MMP2
3
Show member pathways
13.33 AKT1 BCL2 BIRC5 CDKN1A MMP2 TP53
4
Show member pathways
13.02 AKT1 BCL2 BIRC5 CDKN1A TP53 VEGFA
5
Show member pathways
12.94 AKT1 BCL2 CDKN1A TP53 VEGFA
6
Show member pathways
12.93 AKT1 BIRC5 CDKN1A TP53 USP2
7
Show member pathways
12.79 AKT1 BCL2 BIRC5 CDKN1A TP53
8
Show member pathways
12.7 AKT1 BCL2 CDKN1A ESR2 PGR TP53
9 12.58 AKT1 BCL2 BIRC5 CDKN1A ESR2 MMP2
10
Show member pathways
12.51 AKT1 BCL2 BIRC5 CDKN1A TP53 VEGFA
11 12.48 BCL2 CDKN1A TP53 VEGFA
12
Show member pathways
12.48 AKT1 BCL2 BIRC5 CDKN1A MMP2 TP53
13
Show member pathways
12.45 AKT1 CDKN1A TP53 VEGFA
14
Show member pathways
12.39 AKT1 BCL2 CDKN1A ESR2 MMP2 TP53
15
Show member pathways
12.38 AKT1 BIRC5 CDKN1A TP53
16 12.28 AKT1 BCL2 CDKN1A TP53
17 12.25 AKT1 CDKN1A MMP2 TP53 VEGFA
18
Show member pathways
12.24 AKT1 BCL2 CDKN1A TP53
19
Show member pathways
12.19 AKT1 BCL2 CDKN1A TP53
20 12.14 AKT1 BCL2 TP53 VEGFA
21
Show member pathways
12.13 AKT1 CDKN1A TP53 VEGFA
22 12.06 AKT1 CDKN1A TP53 YAP1
23 12.05 BCL2 CDKN1A MMP2 TP53
24 12.02 AKT1 BCL2 MMP2 TP53 VEGFA
25 12 BCL2 CDKN1A MMP2 TP53 VEGFA
26 11.97 AKT1 BCL2 TP53
27 11.97 AKT1 BCL2 CDKN1A TP53
28 11.95 AKT1 BCL2 CDKN1A TP53 USP2
29 11.93 AKT1 CDKN1A TP53
30 11.92 BCL2 CDKN1A MMP14 TP53
31 11.89 AKT1 BCL2 CDKN1A VEGFA
32 11.88 AKT1 BCL2 MMP2 VEGFA
33 11.84 AKT1 BCL2 CDKN1A TP53
34 11.79 AKT1 CDKN1A TP53
35
Show member pathways
11.73 AKT1 TP53 USP2
36 11.72 AKT1 BIRC5 CDKN1A MMP14 MMP2 TP53
37 11.7 CDKN1A MMP2 TP53 VEGFA
38 11.68 AKT1 MMP14 MMP2
39
Show member pathways
11.65 BIRC5 MMP2 VEGFA
40 11.63 AKT1 BCL2 BIRC5 CDKN1A TP53
41 11.61 AKT1 CDKN1A VEGFA
43 11.5 BCL2 CDKN1A MMP2 TP53
44 11.47 AKT1 BCL2 BIRC5
45 11.42 AKT1 BCL2 BIRC5
46 11.42 AKT1 BCL2 CDKN1A TP53
47 11.38 BIRC5 TP53 VEGFA
48 11.3 AKT1 BCL2 YAP1
49 11.28 AKT1 BIRC5 TP53
50 11.26 AKT1 BIRC5 CDKN1A TP53 VEGFA

GO Terms for Serous Cystadenocarcinoma

Cellular components related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.97 AKT1 BCL2 BIRC5 CDKN1A MMP14 MMP2
2 mitochondrion GO:0005739 9.8 AKT1 BCL2 ESR2 MMP2 PGR TP53
3 nucleoplasm GO:0005654 9.65 AKT1 BCL2 BIRC5 CDKN1A ESR2 PGR
4 nucleus GO:0005634 9.47 AKT1 BCL2 BIRC5 CDKN1A ESR2 MMP14

Biological processes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.92 AKT1 BCL2 BIRC5 VEGFA YAP1
2 regulation of apoptotic process GO:0042981 9.9 AKT1 BCL2 BIRC5 TP53
3 cellular response to DNA damage stimulus GO:0006974 9.88 AKT1 BCL2 CDKN1A TP53 YAP1
4 negative regulation of gene expression GO:0010629 9.8 AKT1 CDKN1A PGR VEGFA
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.72 AKT1 BCL2 VEGFA
6 positive regulation of cell growth GO:0030307 9.71 AKT1 BCL2 MMP14
7 transcription initiation from RNA polymerase II promoter GO:0006367 9.71 CDKN1A ESR2 PGR YAP1
8 response to hyperoxia GO:0055093 9.62 CDKN1A TP53
9 response to oxidative stress GO:0006979 9.62 AKT1 BCL2 MMP14 TP53
10 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.61 CDKN1A TP53
11 positive regulation of leukocyte migration GO:0002687 9.61 TP53 VEGFA
12 growth GO:0040007 9.59 BCL2 VEGFA
13 regulation of mitochondrial membrane permeability GO:0046902 9.58 BCL2 TP53
14 replicative senescence GO:0090399 9.58 CDKN1A TP53
15 positive regulation of organ growth GO:0046622 9.57 AKT1 YAP1
16 response to UV-B GO:0010224 9.56 BCL2 TP53
17 negative regulation of cell growth GO:0030308 9.56 BCL2 CDKN1A ESR2 TP53
18 ovarian follicle development GO:0001541 9.54 BCL2 MMP14 VEGFA
19 progesterone receptor signaling pathway GO:0050847 9.51 PGR YAP1
20 circadian behavior GO:0048512 9.46 TP53 USP2
21 signal transduction by p53 class mediator GO:0072331 9.43 CDKN1A TP53
22 cellular response to gamma radiation GO:0071480 9.33 CDKN1A TP53 YAP1
23 cellular response to hypoxia GO:0071456 9.26 AKT1 BCL2 TP53 VEGFA
24 negative regulation of apoptotic process GO:0043066 9.1 AKT1 BCL2 BIRC5 CDKN1A TP53 VEGFA

Molecular functions related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.86 AKT1 ALPP BCL2 BIRC5 CDKN1A ESR2
2 zinc ion binding GO:0008270 9.8 ALPP ESR2 MMP14 MMP2 PGR TP53
3 ubiquitin protein ligase binding GO:0031625 9.71 BCL2 CDKN1A TP53 USP2
4 enzyme binding GO:0019899 9.65 AKT1 BIRC5 ESR2 PGR TP53
5 protein phosphatase 2A binding GO:0051721 9.33 AKT1 BCL2 TP53
6 identical protein binding GO:0042802 9.23 AKT1 BCL2 BIRC5 ESR2 PGR TP53
7 metal ion binding GO:0046872 10.07 ALPP BIRC5 CDKN1A ESR2 MMP14 MMP2

Sources for Serous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....